Acute liver failure from anti-tuberculosis drug-induced liver injury: An update

Table 1 Magnitude of anti-tuberculosis drug-induced acute liver failure in various published studies

Ref.	Study design	n (diagnosis)	n (AT-DILI)	n (AT-ALF)	Proportion of AT-ALF
Anand et al[44], 2006	Observational	152 (TB)	22 (13.8%)	09	13% of prospective cohort (6/69)
Pande et al[22], 1996	Prospective, case-control	492 (TB)	86	05	5.8% of AT-DILI
Devarbhavi et al[26], 2013	Retro-prospective cohort	269 (AT-DILI)	269	69	25.7% of AT-DILI
Dawra et al[24], 2029	Retrospective cohort	141 (TB)	10	01	10% of AT-DILI
Latief et al[23], 2017	Prospective cohort	200 (TB)	16	01	6.2% of AT-DILI
Raj Mani et al[13], 2021	Prospective cohort	397 (TB)	38	04	10.5% of AT-DILI
Kumar et al[19], 2010	Retrospective analysis	1223 (ALF)	-	70	5.7% of ALF
Wang et al[27], 2020	Retrospective analysis	155 (AT-DILI)	155	55	35.4% of AT-DILI
Ichai et al[28], 2010	Retrospective analysis	566 (ALF)	-	14	2.47% of ALF
Mindikoglu et al[29], 2009	Retrospective analysis	661 (drug-induced ALF)	-	50	7.5% of drug-induced ALF

TB: Tuberculosis; ALF: Acute liver failure; AT-ALF: Anti-tuberculosis drug-induced acute liver failure; AT-DILI: Anti-tuberculosis drug-induced liver injury.